肿瘤防治研究2025，Vol.52Issue(2)：87-92,6.DOI:10.3971/j.issn.1000-8578.2025.24.1062
HER-2突变晚期非小细胞肺癌的研究进展
Progress of Research on Advanced Non-Small Cell Lung Cancer with HER-2 Mutation
摘要
Abstract
Anti-tumor drug research and development in non-small cell lung cancer(NSCLC)is rapidly developing,and the clinical application of high-throughput sequencing technology is also becoming widespread.Accordingly,researchers are focusing on human epidermal growth factor receptor-2(HER-2)gene as a rare target of NSCLC,and a series of exploratory studies has been performed.Traditional chemotherapy and immunotherapy are unsatisfactory in the HER-2 mutant population,whereas the survival improvement of anti-HER-2 monoclonal antibodies and pan-HER inhibitors is limited.The development of antibody drug conjugate(ADC)ushers in a turning point for HER-2-mutated NSCLC,and new ADC drugs represented by trastuzumab deruxtecan are making a breakthrough.It opens up a new era of precision therapy for advanced HER-2-mutated NSCLC.Additionally,novel HER-2 inhibitors show very encouraging initial efficacy and safety,and clinical trials are ongoing.This review focuses on the latest progress of research on HER-2-mutated NSCLC.关键词
非小细胞肺癌/HER-2突变/抗体偶联药物/HER-2抑制剂Key words
Non-small cell lung cancer/HER-2 mutation/Antibody drug conjugate/HER-2 inhibitors分类
临床医学引用本文复制引用
张良,杨长良,李佩东,程颖..HER-2突变晚期非小细胞肺癌的研究进展[J].肿瘤防治研究,2025,52(2):87-92,6.基金项目
Science and Technology Department of Jilin Province Project(No.YDZJ202401425ZYTS,20220203150SF) 吉林省科技厅项目(YDZJ202401425ZYTS,20220203150SF) （No.YDZJ202401425ZYTS,20220203150SF）
